Emmaus Life Sciences, INC. 8-K Filing

Ticker: EMMA · Form: 8-K · Filed: Dec 31, 2025 · CIK: 822370

Sentiment: neutral

Filing Stats: 902 words · 4 min read · ~3 pages · Grade level 11.9 · Accepted 2025-12-30 18:32:39

Filing Documents

01 Entry into a Material Definitive Agreement

Item 1.01 Entry into a Material Definitive Agreement On December 24, 2025, Emmaus Life Sciences, Inc. ("we," "us," "our," "Emmaus" and the "company") and NeoImmuneTech, Inc. (KOSDAQ: 950220.KQ), or NIT, entered into a License and Exclusive Distribution Agreement, or License Agreement, dated as of the same day pursuant to which we granted NIT an exclusive (including as to Emmaus) license to all our rights to market, sell and distribute Endari (prescription grade L-glutamine oral powder) and any generic equivalents, or the Products, in sickle cell disease, or the Field, in the U.S. and its territories and possession and Canada, referred to as the Territory, in exchange for an upfront payment and a royalty on NIT's Product sales. A portion of the upfront payment was paid in cash upon execution of the License Agreement, with the balance payable upon the "Effective Date" of the License Agreement. In connection with the Effective Date, we and NIT will enter into an exclusive supply arrangement pursuant to which we will agree to supply exclusively to NIT, and NIT will agree, subject to certain exceptions, to purchase exclusively from us all NIT's requirements for the Products in the Field in the Territory at a purchase price based upon our cost of production plus an agreed margin. Pending the Effective Date, we facilitate the transfer and employment by NIT of selected members of our U.S. sales force. The Effective Date is subject to NIT's obtaining the necessary regulatory approvals and licensing to sell and distribute the Product and other specified conditions, and there is no assurance that the Effective Date will occur. The License Agreement may be terminated by either party if the Effective Date has not occurred by October 1, 2026 unless the failure to occur is due to our wrongful acts. Once the Effective Date occurs, the rights granted NIT under the License Agreement will become nonexclusive if NIT fails to generate specified annual minimum sales of Products. Fol

01 Other Events

Item 8.01 Other Events. On December 30, 2025, Emmaus issued a press release announcing the License Agreement and related matters. A copy of the press release is filed as Exhibit 99.1 to this Current Report and incorporated herein by reference.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits (d) Exhibits See the accompanying Index to Exhibits, which information is incorporated herein by reference. 1

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: December 30 , 2025 Emmaus Life Sciences, Inc. By: /s/ WILLIS LEE Willis Lee Chairman and Chief Executive Officer 2 INDEX TO EXHIBITS Exhibit Number Description 99.1 Press release issued December 30, 2025 104 Cover Page Interactive Date File (embedded within Inline XBRL document) 3

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing